Sun Pharma and Incyte settle LEQSELVI litigation; Sun gains U.S. license for deuruxolitinib in certain non-cancer uses.

• Parties to dismiss U.S. litigation, mutually releasing all claims related to deuruxolitinib patent dispute.
• Sun receives limited U.S. license for deuruxolitinib in non-hematology-oncology uses like alopecia areata.
• Sun will pay upfront and royalties to Incyte; exact financial details of the agreement remain confidential.